New liquid biopsy test unveiled for mesothelioma
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer.
The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies.
Diagnosis today requires several steps, including a CT scan and an invasive biopsy. Mesothelioma typically is not diagnosed until it has reached an advanced stage when treatment options are limited and survival times are short.